PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
30-Mar-2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac
30-Mar-2022 New analysis shows that Kesimpta®▼ (ofatumumab)-treated adults with relapsing remitting multiple sclerosis (RRMS) are not at increased risk of severe COVID-19 infections Novartis
30-Mar-2022 M1 Kliniken AG publishes preliminary figures for financial year 2021: revenue rises to € 315 million; pre-tax profit amounts to € 14.4 million M1 Kliniken AG
30-Mar-2022 Grünenthal achieves record 2021 results with double-digit growth and major investments in portfolio and pipeline Grünenthal GmbH
30-Mar-2022 HAEMATO AG - preliminary figures for the 2021 financial year: Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit HAEMATO AG
30-Mar-2022 PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD PAION AG
30-Mar-2022 Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook Eckert & Ziegler Strahlen- und Medizintechnik AG
30-Mar-2022 ​​​​​​​PAION AG REPORTS ON FISCAL YEAR 2021 PAION AG
30-Mar-2022 STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR STRATEC SE
29-Mar-2022 Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG Formycon AG
29-Mar-2022 Formycon and ATHOS KG merge development activities through the acquisition of biosimilar assets in a long-term strategic partnership Formycon AG
29-Mar-2022 Rentschler Biopharma and Vetter Unveil Xpert Alliance, a Joint Visualization of their Successful Strategic Collaboration Rentschler Biopharma
29-Mar-2022 Rentschler Biopharma and Vetter Unveil Xpert Alliance, a Joint Visualization of their Successful Strategic Collaboration B3C newswire
29-Mar-2022 Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix® (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients Hansa Biopharma
29-Mar-2022 Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy Santhera Pharmaceuticals
29-Mar-2022 Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver Sanofi
29-Mar-2022 European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B CSL Behring
29-Mar-2022 Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency Sanofi
29-Mar-2022 Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020 Novo Holdings
29-Mar-2022 Oxurion to Participate in Needham Virtual Healthcare Conference Oxurion